PD-Rx Pharmaceuticals, Inc. (PDRX)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
PD-Rx Pharmaceuticals, Inc. (PDRX) with AI Score 44/100 (Weak). PD-Rx Pharmaceuticals, Inc. focuses on repackaging and distributing prepackaged pharmaceutical products to healthcare providers in the United States. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 16, 2026PD-Rx Pharmaceuticals, Inc. (PDRX) Healthcare & Pipeline Overview
PD-Rx Pharmaceuticals, Inc., established in 1986, operates within the medical distribution sector, providing prepackaged medications and dispensing solutions to healthcare providers across the United States. The company's offerings include a variety of medications, web-based prescription tracking, and pharmaceutical sampling programs, serving physicians, pharmacies, and medical clinics.
Investment Thesis
PD-Rx Pharmaceuticals, Inc. operates in the niche market of prepackaged pharmaceutical distribution, offering convenience to healthcare providers. However, the company's negative profit margin of -1.4% and a P/E ratio of -19.98 indicate financial challenges. The beta of -1366978.48 suggests an inverse correlation with the market, which can be both a risk and an opportunity. Growth catalysts include expanding its PD-Rx Net platform and pharmaceutical sampling programs. The company's ability to achieve profitability and manage its cost structure will be critical for long-term success. Investors should closely monitor its financial performance and competitive positioning within the medical distribution sector.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.01 billion indicates a small-cap company.
- Negative P/E ratio of -19.98 suggests the company is currently not profitable.
- Profit margin of -1.4% reflects operational inefficiencies or pricing pressures.
- Beta of -1366978.48 indicates an inverse correlation with the market, suggesting the stock may move opposite to market trends.
- No dividend yield, indicating the company is not currently returning profits to shareholders.
Competitors & Peers
Strengths
- Established presence in the prepackaged pharmaceutical distribution market.
- Proprietary PD-Rx Net platform for prescription tracking.
- Comprehensive range of prepackaged medications.
- Pharmaceutical sampling program design expertise.
Weaknesses
- Negative profit margin indicates financial instability.
- Small market capitalization limits access to capital.
- High beta suggests significant volatility.
- Dependence on a niche market segment.
Catalysts
- Ongoing: Expansion of PD-Rx Net platform to attract more customers and increase subscription revenue.
- Ongoing: Strategic partnerships with medical clinics to drive sales and expand market reach.
- Upcoming: Potential regulatory changes in the pharmaceutical industry that could benefit smaller distributors.
- Ongoing: Development of new pharmaceutical sampling programs to reduce costs for MCOs.
- Ongoing: Geographic expansion to new regions within the United States to tap into untapped markets.
Risks
- Ongoing: Intense competition from larger pharmaceutical distributors with greater resources.
- Potential: Economic downturn affecting healthcare spending and reducing demand for pharmaceutical products.
- Potential: Regulatory changes impacting the pharmaceutical industry and increasing compliance costs.
- Potential: Product liability claims arising from the distribution of pharmaceutical products.
- Ongoing: The company's financial instability, with a negative profit margin and P/E ratio.
Growth Opportunities
- Expansion of PD-Rx Net Platform: The company can focus on enhancing and expanding its PD-Rx Net platform, a web-based application that tracks prescriptions filled at the point of care. By adding more features and integrations, PD-Rx can attract more physicians and pharmacies, increasing its market share. The market for healthcare IT solutions is projected to reach $390 billion by 2027, offering a significant growth opportunity.
- Pharmaceutical Sampling Program Design: PD-Rx Pharmaceuticals can further develop its pharmaceutical sampling program design to reduce pharmaceutical costs for MCOs. This program allows medical professionals to offer pre-filled prescriptions to patients free of charge. As healthcare costs continue to rise, MCOs are actively seeking cost-saving solutions, making this a viable growth area. The pharmaceutical sampling market is estimated to be worth $20 billion annually.
- Strategic Partnerships with Medical Clinics: Forming strategic partnerships with medical clinics to provide prepackaged medications and dispensing solutions can drive revenue growth. By offering a comprehensive suite of services, PD-Rx can become an integral part of the clinic's operations, ensuring a steady stream of orders. The number of medical clinics is growing at a rate of 3% annually, presenting a large potential market.
- Geographic Expansion: Expanding its operations to new geographic regions within the United States can significantly increase PD-Rx's customer base. By targeting states with a high concentration of physicians and pharmacies, the company can capitalize on untapped markets. The US pharmaceutical market is the largest in the world, with a value of over $500 billion, offering ample opportunities for growth.
- Development of Specialty Medication Packaging: Focusing on the development of specialized packaging solutions for specialty medications can cater to a growing niche market. Specialty medications often require specific handling and storage conditions, creating a demand for specialized packaging. The specialty pharmaceutical market is growing at a rate of 8% annually, driven by the increasing prevalence of chronic diseases and the development of innovative therapies.
Opportunities
- Expansion of PD-Rx Net platform to attract more customers.
- Strategic partnerships with medical clinics to increase sales.
- Geographic expansion to new regions within the United States.
- Development of specialty medication packaging solutions.
Threats
- Increasing competition from larger pharmaceutical distributors.
- Regulatory changes impacting the pharmaceutical industry.
- Economic downturn affecting healthcare spending.
- Potential for product liability claims.
Competitive Advantages
- Established relationships with physicians, pharmacies, and medical clinics.
- Proprietary PD-Rx Net web-based application for prescription tracking.
- Specialized expertise in repackaging and distributing prepackaged medications.
- Pharmaceutical sampling program design capabilities.
About PDRX
PD-Rx Pharmaceuticals, Inc., founded in 1986 and headquartered in Oklahoma City, Oklahoma, operates within the healthcare industry, specializing in the repackaging and distribution of prepackaged pharmaceutical products. The company serves a diverse clientele, including physicians, pharmacies, and medical clinics throughout the United States. PD-Rx Pharmaceuticals offers a comprehensive portfolio of approximately 2,600 prepackaged medications, encompassing creams, ointments, ophthalmics, otics, liquids, and suspensions. Beyond its distribution capabilities, PD-Rx Pharmaceuticals provides technological solutions to streamline prescription management. PD-Rx Net, a web-based application, enables healthcare providers to track prescriptions filled at the point of care and print prescription labels for onsite dispensing. Additionally, the company offers a manual dispensing system, complete with recordkeeping labels, designed for physician dispensing customers. PD-Rx Pharmaceuticals also distinguishes itself through its commitment to customer support and cost-effectiveness. The company provides professional assistance from staffed pharmacists and physicians, ensuring that clients receive expert guidance and support. Furthermore, PD-Rx Pharmaceuticals designs pharmaceutical sampling programs aimed at reducing pharmaceutical costs for Managed Care Organizations (MCOs), while also enabling medical professionals to offer pre-filled prescriptions to patients free of charge.
What They Do
- Repackages and distributes prepackaged pharmaceutical products.
- Provides approximately 2,600 prepackaged medications.
- Offers creams, ointments, ophthalmics, otics, liquids, and suspensions.
- Provides PD-Rx Net, a web-based application for prescription tracking.
- Offers a manual dispensing system with recordkeeping labels.
- Provides professional assistance from staffed pharmacists and physicians.
- Designs pharmaceutical sampling programs to reduce MCO's pharmaceutical costs.
Business Model
- Generates revenue through the sale of prepackaged medications to physicians, pharmacies, and medical clinics.
- Offers PD-Rx Net subscription for prescription tracking and label printing.
- Provides pharmaceutical sampling program design services to MCOs.
- Offers manual dispensing systems and related supplies.
Industry Context
PD-Rx Pharmaceuticals, Inc. operates within the medical distribution industry, which is characterized by increasing demand for efficient pharmaceutical supply chains and point-of-care dispensing solutions. The industry is influenced by factors such as regulatory changes, technological advancements, and the growing emphasis on cost containment within the healthcare system. Competitors like CPIVF, FZMD, IDXG, KOSK, and MVMDF operate in similar spaces, providing various pharmaceutical products and services. PD-Rx Pharmaceuticals differentiates itself through its focus on prepackaged medications and its PD-Rx Net platform.
Key Customers
- Physicians
- Pharmacies
- Medical Clinics
Financials
Chart & Info
PD-Rx Pharmaceuticals, Inc. (PDRX) stock price: Price data unavailable
Latest News
No recent news available for PDRX.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PDRX.
Price Targets
Wall Street price target analysis for PDRX.
MoonshotScore
What does this score mean?
The MoonshotScore rates PDRX's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Robert D. Holsey
CEO
Robert D. Holsey serves as the Chief Executive Officer of PD-Rx Pharmaceuticals, Inc. His background includes extensive experience in the pharmaceutical distribution industry. He has been involved in various aspects of the business, including sales, marketing, and operations. Holsey's leadership is focused on driving growth and profitability through strategic partnerships and innovative solutions. His expertise in the healthcare sector allows him to navigate the complexities of the market and identify opportunities for expansion.
Track Record: Under Robert D. Holsey's leadership, PD-Rx Pharmaceuticals, Inc. has focused on expanding its product offerings and strengthening its customer relationships. Key milestones include the development and launch of the PD-Rx Net platform and the implementation of pharmaceutical sampling programs. Despite financial challenges, Holsey has worked to streamline operations and improve efficiency. The company's focus remains on providing value-added services to its clients.
PDRX OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that PD-Rx Pharmaceuticals, Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not provide regular financial disclosures. Investing in companies on the OTC Other tier carries a higher degree of risk compared to those listed on major exchanges like the NYSE or NASDAQ due to the lack of regulatory oversight and transparency.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases the risk of investing in PDRX.
- Low trading volume and wide bid-ask spread can lead to price volatility.
- Lack of regulatory oversight on the OTC Other tier increases the risk of fraud or mismanagement.
- The company's financial performance is currently weak, with a negative profit margin and P/E ratio.
- Small market capitalization makes the company vulnerable to market fluctuations.
- Verify the company's financial statements and SEC filings (if available).
- Assess the company's management team and their track record.
- Evaluate the company's competitive positioning within the medical distribution industry.
- Analyze the company's revenue streams and customer base.
- Determine the company's debt levels and cash flow.
- Understand the company's regulatory compliance and legal risks.
- Assess the liquidity of the stock and the potential for price volatility.
- The company has been in operation since 1986, indicating a long history in the industry.
- PD-Rx Pharmaceuticals, Inc. provides a specific service within the healthcare industry.
- The company has a CEO, Robert D. Holsey, suggesting leadership and direction.
- The company offers a web-based application, PD-Rx Net, suggesting technological capabilities.
- The company serves physicians, pharmacies, and medical clinics, indicating a customer base.
PDRX Healthcare Stock FAQ
What does PD-Rx Pharmaceuticals, Inc. do?
PD-Rx Pharmaceuticals, Inc. specializes in the repackaging and distribution of prepackaged pharmaceutical products to healthcare providers across the United States. The company offers a diverse range of approximately 2,600 prepackaged medications, including creams, ointments, ophthalmics, otics, liquids, and suspensions. In addition to its distribution services, PD-Rx Pharmaceuticals provides technological solutions such as the PD-Rx Net platform, which enables healthcare providers to track prescriptions and print labels. The company also designs pharmaceutical sampling programs to reduce costs for Managed Care Organizations (MCOs).
What do analysts say about PDRX stock?
As of March 16, 2026, formal analyst ratings for PD-Rx Pharmaceuticals, Inc. (PDRX) are not widely available, likely due to its OTC listing and small market capitalization. Key valuation metrics, such as the negative P/E ratio and profit margin, suggest financial challenges. Growth considerations revolve around the company's ability to expand its PD-Rx Net platform, form strategic partnerships, and manage its cost structure. Investors should conduct their own thorough research and consider the risks associated with investing in OTC stocks.
What are the main risks for PDRX?
The main risks for PD-Rx Pharmaceuticals, Inc. include intense competition from larger pharmaceutical distributors, regulatory changes impacting the pharmaceutical industry, and economic downturns affecting healthcare spending. The company's financial instability, with a negative profit margin and P/E ratio, also poses a significant risk. Additionally, its listing on the OTC Other tier carries increased risks due to limited financial disclosure, low trading volume, and a lack of regulatory oversight. Investors should carefully consider these risks before investing in PDRX.
What are the key factors to evaluate for PDRX?
PD-Rx Pharmaceuticals, Inc. (PDRX) currently holds an AI score of 44/100, indicating low score. Key strength: Established presence in the prepackaged pharmaceutical distribution market.. Primary risk to monitor: Ongoing: Intense competition from larger pharmaceutical distributors with greater resources.. This is not financial advice.
How frequently does PDRX data refresh on this page?
PDRX prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven PDRX's recent stock price performance?
Recent price movement in PD-Rx Pharmaceuticals, Inc. (PDRX) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Established presence in the prepackaged pharmaceutical distribution market.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider PDRX overvalued or undervalued right now?
Determining whether PD-Rx Pharmaceuticals, Inc. (PDRX) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying PDRX?
Before investing in PD-Rx Pharmaceuticals, Inc. (PDRX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Financial data is based on the most recent available information.
- OTC market data may be limited and less reliable than data from major exchanges.
- AI analysis is pending and may provide further insights.